Protocol Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Target Population: Newly diagnosed and previously untreated Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 1 (IDH1) Mutation

Summary: Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (Ivosidenib) + Azacitidine vs. placebo + Azacitidine in adult subjects with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy.

Key Inclusion Criteria:
• Have previously untreated AML with ≥ 20% leukemic blasts in the bone marrow.
  o Subjects with extramedullary disease alone (i.e., no detectable bone marrow and no detectable peripheral blood AML) are not eligible for the study.
• Have an Isocitrate Dehydrogenase 1 (IDH1) Mutation.
• ECOG Performance Status score of 0 to 2.
• Have adequate hepatic and renal function.
• Have agreed to undergo serial blood and bone marrow sampling.

Key Exclusion Criteria:
• Are candidates for and willing to receive intensive IC for their AML.
• Have received any prior treatment for AML with the exception of hydroxyurea.
• Have received a hypomethylating agent for Myelodysplastic Syndrome (MDS).
• Subjects who had previously received an experimental agent for MDS may not be randomized until a washout period has elapsed since the last dose of that agent.
• Have received prior treatment with an IDH1 Inhibitor.
• Have a known hypersensitivity to any of the components of AG-120, matched placebo, or Azacitidine.
• Have an active, uncontrolled, systemic fungal, bacterial, or viral infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.
• Have a prior history of cancer other than MDS or Myeloproliferative Disorder, unless the subject has been free of the disease for ≥ 1 Year prior to the start of study treatment.
• Have had significant active cardiac disease within 6 Months prior to the start of study treatment.
• Have any condition that increases the risk of abnormal ECG or cardiac arrhythmia.
• Have a condition that limits the ingestion or absorption of drugs administered by mouth.
• Have uncontrolled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg).
• Have clinical symptoms suggestive of active CNS Leukemia or known CNS Leukemia.
• Have immediate, life-threatening, severe complications of leukemia, such as uncontrolled bleeding, pneumonia with hypoxia or sepsis, and/or disseminated intravascular coagulation.
• Have any other medical or psychological condition deemed by the Investigator to be likely to interfere with the subject's ability to give informed consent or participate in the study.

Contacts:
Principal Investigator: Andrew Dalovisio, MD
Research Nurses (RN): Elise Curry (elisemarie.curry@ochsner.org, ext. 28084)
  Stephanie Green (stephanie.green2@ochsner.org, ext. 23918)

For additional information: https://clinicaltrials.gov/ct2/show/NCT03173248